110 related articles for article (PubMed ID: 27476292)
1. DISSOLUTION AND COMPATIBILITY STUDY OF BINARY AND TERNARY INTERACTIVE MIXTURES OF INDOMETHACIN: COMPARISON WITH COMMERCIALLY AVAILABLE CAPSULES.
Maswadeh HM
Acta Pol Pharm; 2016; 73(3):739-48. PubMed ID: 27476292
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of the dissolution of indomethacin in interactive mixtures using added fine lactose.
Allahham A; Stewart PJ
Eur J Pharm Biopharm; 2007 Nov; 67(3):732-42. PubMed ID: 17540551
[TBL] [Abstract][Full Text] [Related]
3. Bioavailability studies on fast release formulations of indomethacin.
Verma MM; Kumar MT; Balasubramaniam J; Pandit JK
Boll Chim Farm; 2002; 141(3):176-80. PubMed ID: 12197414
[TBL] [Abstract][Full Text] [Related]
4. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles.
Fini A; Cavallari C; Ospitali F
Eur J Pharm Biopharm; 2008 Sep; 70(1):409-20. PubMed ID: 18621516
[TBL] [Abstract][Full Text] [Related]
5. Characterization of physico-mechanical properties of indomethacin and polymers to assess their suitability for hot-melt extrusion processs as a means to manufacture solid dispersion/solution.
Chokshi RJ; Sandhu HK; Iyer RM; Shah NH; Malick AW; Zia H
J Pharm Sci; 2005 Nov; 94(11):2463-74. PubMed ID: 16200544
[TBL] [Abstract][Full Text] [Related]
6. Solid-state interaction of stearic acid with povidone and its effect on dissolution stability of capsules.
Desai D; Kothari S; Huang M
Int J Pharm; 2008 Apr; 354(1-2):77-81. PubMed ID: 18194844
[TBL] [Abstract][Full Text] [Related]
7. Stabilization of low glass transition temperature indomethacin formulations: impact of polymer-type and its concentration.
Chokshi RJ; Shah NH; Sandhu HK; Malick AW; Zia H
J Pharm Sci; 2008 Jun; 97(6):2286-98. PubMed ID: 17879977
[TBL] [Abstract][Full Text] [Related]
8. Formation and characterization of porous indomethacin-PVP coprecipitates prepared using solvent-free supercritical fluid processing.
Gong K; Viboonkiat R; Rehman IU; Buckton G; Darr JA
J Pharm Sci; 2005 Dec; 94(12):2583-90. PubMed ID: 16258991
[TBL] [Abstract][Full Text] [Related]
9. Phase behavior of binary and ternary amorphous mixtures containing indomethacin, citric acid, and PVP.
Lu Q; Zografi G
Pharm Res; 1998 Aug; 15(8):1202-6. PubMed ID: 9706050
[TBL] [Abstract][Full Text] [Related]
10. A comparison of spray drying and milling in the production of amorphous dispersions of sulfathiazole/polyvinylpyrrolidone and sulfadimidine/polyvinylpyrrolidone.
Caron V; Tajber L; Corrigan OI; Healy AM
Mol Pharm; 2011 Apr; 8(2):532-42. PubMed ID: 21323367
[TBL] [Abstract][Full Text] [Related]
11. Understanding improved dissolution of indomethacin through the use of cohesive poorly water-soluble aluminium hydroxide: effects of concentration and particle size distribution.
Tay T; Allahham A; Morton DA; Stewart PJ
J Pharm Sci; 2011 Oct; 100(10):4269-80. PubMed ID: 21560127
[TBL] [Abstract][Full Text] [Related]
12. Influence of excipients on solubility and dissolution of pharmaceuticals.
Paus R; Prudic A; Ji Y
Int J Pharm; 2015 May; 485(1-2):277-87. PubMed ID: 25749073
[TBL] [Abstract][Full Text] [Related]
13. Clarification of the Dissolution Mechanism of an Indomethacin/Saccharin/Polyvinylpyrrolidone Ternary Solid Dispersion by NMR Spectroscopy.
Kosaka M; Higashi K; Nishimura M; Ueda K; Moribe K
J Pharm Sci; 2020 Dec; 109(12):3617-3624. PubMed ID: 32931779
[TBL] [Abstract][Full Text] [Related]
14. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen.
Löbmann K; Laitinen R; Grohganz H; Gordon KC; Strachan C; Rades T
Mol Pharm; 2011 Oct; 8(5):1919-28. PubMed ID: 21815614
[TBL] [Abstract][Full Text] [Related]
15. Release of indomethacin from ultrasound dry granules containing lactose-based excipients.
Cavallari C; Albertini B; Rodriguez L; Rabasco AM; Fini A
J Control Release; 2005 Jan; 102(1):39-47. PubMed ID: 15653132
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of beta-lactose, PVP K12 and PVP K90 as excipients to prepare piroxicam granules using two wet granulation techniques.
Albertini B; Cavallari C; Passerini N; González-Rodríguez ML; Rodriguez L
Eur J Pharm Biopharm; 2003 Nov; 56(3):479-87. PubMed ID: 14602193
[TBL] [Abstract][Full Text] [Related]
17. Characterization of ibuproxam binary and ternary dispersions with hydrophilic carriers.
Cirri M; Mura P; Rabasco AM; Ginés JM; Moyano JR; Gònzalez-Rodrìguez ML
Drug Dev Ind Pharm; 2004 Jan; 30(1):65-74. PubMed ID: 15000431
[TBL] [Abstract][Full Text] [Related]
18. Counter-intuitive enhancement in the dissolution of indomethacin with the incorporation of cohesive poorly water-soluble inorganic salt additives.
Tay T; Allahham A; Morton DA; Stewart PJ
Eur J Pharm Biopharm; 2011 Nov; 79(3):674-82. PubMed ID: 21703348
[TBL] [Abstract][Full Text] [Related]
19. Molecular dynamics simulation of amorphous indomethacin-poly(vinylpyrrolidone) glasses: solubility and hydrogen bonding interactions.
Xiang TX; Anderson BD
J Pharm Sci; 2013 Mar; 102(3):876-91. PubMed ID: 23280486
[TBL] [Abstract][Full Text] [Related]
20. Improving the de-agglomeration and dissolution of a poorly water soluble drug by decreasing the agglomerate strength of the cohesive powder.
Allahham A; Stewart PJ; Das SC
Int J Pharm; 2013 Nov; 457(1):101-9. PubMed ID: 24080334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
